Management Team

Börje Haraldsson

Chief Executive Officer and Chief Scientific Officer

MD, PhD, FASN, FAST, Professor Haraldsson has served for 15 years as Chair of nephrology at the University of Gothenburg, Sweden, and as senior consultant at the nephrology clinic at Sahlgrenska University hospital, Gothenburg. Most recently, he initiated and lead high-profile global drug development projects in nephrology, transplantation, and rheumatology at Novartis, Switzerland. Read more about Börje Haraldsson here.

Pål Falck

Chief Business Officer and Deputy CEO

MBA, PhD in Clinical Nephrology focused Pharmacokinetics. Pål Falck has a broad background within the life science sector including Nordic Medical Director in Oncology & Infections at AstraZeneca, Medical Advisor and Business Development at Pfizer Norway, Healthcare Equity Research Analyst at Arctic Securities in Norway.

Susanna Dahlgren

Chief Operating Officer

PhD in Clinical Immunology Karolinska Institute, PMP.. Susanna Dahlgren has a long experience in drug development from various positions in the pharmaceutical industry including Astrazeneca, ALK, Polypeptide, Aqilion and SDS Life Science, focusing on project leadership from early drug discovery to clinical development, medical affairs and scientific marketing. Read more about Susanna Dahlgren here.

Jack Welch

Chief Medical Officer

MD, PhD in Pharmacology. Jack was fellowship trained in Paediatric Haematology-Oncology at Children’s Hospital of Philadelphia, then transitioned to adult cancer clinical trials as Senior Clinical Research Physician at the European Organisation for Research and Treatment of Cancer (EORTC) and Senior Investigator at the US National Cancer Institute’s CTEP Office for over a decade.

Åsa Holmgren

Head of Regulatory Affairs

MSc Pharm from Uppsala University. Åsa Holmgren has over 30 years of experience in Global Strategic Regulatory Affairs and Drug Development in pharmaceutical companies. She has held leadership positions and led regulatory strategies at Medivir AB, Orexo AB, AstraZeneca R&D, Pharmacia & Upjohn R&D, and Roche AB. Read more about Åsa Holmgren here.


Relevant experience and expertise

Oncorena continues to build an organization with the necessary skills and experience in drug development as well as a broad and global experience from the pharmaceutical industry that is required to successfully develop and commercialize the Company’s drug candidate for breakthrough treatment of kidney cancer.

Board of Directors

Andreas Segerros

Chairman of the Board

Biochemist by training and brings extensive commercial and business development experience from the global pharmaceutical corporations Pharmacia and Ferring where he has held executive positions in Europe, the US, and Japan. Previously, Venture Partner and Partner at Sunstone Capital in Denmark. Currently, Managing Partner and Board member of Eir Ventures Partners AB.

Björn Odlander

Board member

MD, PhD, co-founder of HealthCap, Managing Partner since 1996. Previous experience includes leading ABB Aros Securities Health Care Equity Research Team. Extensive board experience from the life science sector including Q-Med AB, NicOx SA, Jerini AG, Nordic Nanovector ASA and BoneSupport AB.

Linus Wiebe

Board member

M.Sc in Engineering Physics from Lund University with extensive investment and startup experience, both operationally and as board member. Currently partner in Fåhraeus Startup and Growth, privately held early-stage investment fund. Previously 10+ years responsible for innovation, start-up and investment activities at Lund University, and 15+ in the tech and telecom industry with positions in, e.g. Ericsson and ARM.

Thomas Bergh

Board member

MSc in Economics and Business from Stockholm School of Economics and brings extensive experience from corporate development in Life Science companies. Experience from executive positions in several Life Science focused investment companies. Currently CFO of Linc AB, a listed investment company focused on product-oriented Life Science companies, where he also is part of the investment team responsible for evaluating new investments as well as supporting existing portfolio companies. Previously he was responsible for the investment activities of MedCap AB and prior to that he worked with corporate finance advisory at Morgan Stanley and UBS Investment Bank in London and Stockholm.

Scientific Advisory Board

Michael Atkins, M.D.

Georgetown University Medical Center, Washington DC, US

Deputy Director & Professor. Acting Chief, Division of Hematology/Oncology MedStar Georgetown University Hospital, Washington DC, US.

More info

Petri Bono, M.D.

Terveystalo Hospital, Helsinki, Finland

MD, Chief Medical Officer (CMO) of Terveystalo, Finland and associate professor at University of Helsinki.

More info

Bernard Escudier, M.D.

Institut Gustave Roussy, Villejuif, Paris, France

MD, Chairman of the Genitourinary Tumor Board at Gustave Roussy (2010-2015).

More info

Viktor Grünwald, M.D.

University Hospital Essen in Essen, Germany

Professor for Interdisciplinary Genitourinary Oncology at the University Hospital Essen in Essen, Germany.

More info

Michael Staehler, M.D., Ph.D.

Ludwig-Maximilian-University of Munich, Munich, Germany

Head Renal tumor unit, Maximiliam University, Munich, Germany.

More info

Nizar M. Tannir, M.D., FACP

MD Anderson Cancer Center, Houston, US

MD, Professor, Deputy Department Chair, Department of Genitourinary Medical Oncology, Division of Cancer Medicine. 

More info

Martin Voss, M.D.

Memorial Sloan Kettering Cancer Center, New York, US

Clinical Director, Genitourinary Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, US.

More info